Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations

Clinical and Experimental Metastasis

Volumn 30, Issue 3, 2013, Pages 309-316

  Silvestri, Alessandra ^a,b   Calvert, Valerie ^a   Belluco, Claudio ^b   Lipsky, Michael ^c   De Maria, Ruggero ^d   Deng, Jianghong ^a   Colombatti, Alfonso ^b   De Marchi, Francesco ^b   Nitti, Donato ^e   Mammano, Enzo ^e   Liotta, Lance ^a   Petricoin, Emanuel ^a   Pierobon, Mariaelena ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Colorectal cancer; Metastasis; Protein pathway activation mapping; Proteomics; Reverse phase protein microarray; Tumor microenvironment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; STEM CELL FACTOR; TUMOR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LIVER METASTASIS; MALE; MOLECULAR MECHANICS; PRIMARY TUMOR; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RECTUM; SIGNAL TRANSDUCTION; TRANSVERSE COLON; TUMOR INVASION; COLORECTAL TUMOR; DISEASE COURSE; METABOLISM; METASTASIS; PATHOLOGY; PHOSPHORYLATION; WESTERN BLOTTING;

BLOTTING, WESTERN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS;

MLCS; MLOWN;

EID: 84875775199     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9538-5     Document Type: Article

References (36)

1. Siegel R, Naishadham D (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29
2. Field K, Lipton L (2007) Metastatic colorectal cancer - past, progress and future. World J Gastroenterol 13(28):3806-3815
3. Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22):3677-3683
4. Luzzi KJ, MacDonald IC, Schmidt EE et al (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153(3):865-873
5. Paget S (1989) The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8(2):98-101
6. Joyce T, Pintzas A (2007) Microarray analysis to reveal genes involved in colon carcinogenesis. Expert Opin Pharmacother 8(7):895-900
7. Li M, Lin YM, Hasegawa S et al (2004) Genes associated with liver metastasis of colon cancer identified by genome-wide cDNA microarray. Int J Oncol 24(2):305-312
8. Bertucci F, Salas S, Eysteries S et al (2004) Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23(7):1377-1391
9. Houlston RS (2001) What we could do now: molecular pathology of colorectal cancer. Mol Pathol 54(4):206-214
10. Driouch K, Landemaine T, Sin S et al (2007) Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis. Clin Exp Metastasis 24(8):575-585
11. Mendez E, Fan W, Choi P et al (2007) Tumor-specific genetic expression profile of metastatic oral squamous cell carcinoma. Head Neck 29(9):803-814
12. Petricoin EF III, Bichsel VE, Calvert VS et al (2005) Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 23(15):3614-3621
13. Gulmann C, Sheehan KM, Kay EW et al (2006) Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol 208(5):595-606
14. Wulfkuhle JD, Edmiston KH, Liotta LA et al (2006) Technology insight: pharmacoproteomics for cancer - promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 3(5):256-268
15. Anderson L, Seilhamer J (1997) A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18(3-4):533-537
16. Gygi SP, Rochon Y, Franza BR et al (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19(3):1720-1730
17. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341-354
18. Espina V, Wulfkuhle JD, Calvert VS et al (2006) Laser-capture microdissection. Nat Protoc 1(2):586-603
19. Espina V, Heiby M, Pierobon M et al (2007) Laser capture microdissection technology. Expert Rev Mol Diagn 7(5):647-657
20. VanMeter A, Signore M, Pierobon M et al (2007) Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 7(5):625-633
21. Speer R, Wulfkuhle J, Espina V et al (2007) Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics Proteomics 4(3):157-164
22. Speer R, Wulfkuhle JD, Liotta LA et al (2005) Reverse-phase protein microarrays for tissue-based analysis. Curr Opin Mol Ther 7(3):240-245
23. Espina V, Mehta AI, Winters ME et al (2003) Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3(11):2091-2100
24. Wulfkuhle JD, Speer R, Pierobon M et al (2008) Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 7(4):1508-1517
25. Winters M, Dabir B, Yu M et al (2007) Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics 7(22):4066-4068
26. Pierobon M, Calvert V, Belluco C et al (2009) Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 8(2):110-117
27. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361(25):2449-2460
28. Jones S, Chen WD, Parmigiani G et al (2008) Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 105(11):4283-4288
29. Scartozzi M, Bearzi I, Berardi R et al (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22(23):4772-4778
30. Italiano A, Hostein I, Soubeyran I et al (2010) KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17(5):1429-1434
31. Knijn N, Mekenkamp LJ, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumors and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104(6):1020-1026
32. Vermaat JS, Nijman IJ, Koudijs MJ et al (2012) Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res 18(3):688-699
33. Ericson K, Gan C, Cheong I et al (2010) Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci USA 107(6):2598-2603
34. Rychahou PG, Kang J, Gulhati P et al (2008) Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 105(51):20315-20320
35. Loupakis F, Pollina L, Stasi I et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27(16):2622-2629
36. Espina V, Edmiston KH, Heiby M et al (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7(10):1998-2018